Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9VDZ

hA5-6(W30B/E45) Fab bound to SFTSV glycoprotein Gn

Summary for 9VDZ
Entry DOI10.2210/pdb9vdz/pdb
DescriptorhA5-6(W30B/E45) Fab heavy chain, hA5-6(W30B/E45) Fab light chain, Envelopment polyprotein, ... (5 entities in total)
Functional Keywordsglycoprotein, gn, fab, viral protein/immune system, viral protein-immune system complex
Biological sourceHomo sapiens (human)
More
Total number of polymer chains6
Total formula weight173619.95
Authors
Deng, Z.,Kuang, W.,Zhao, H. (deposition date: 2025-06-09, release date: 2026-01-07, Last modification date: 2026-02-25)
Primary citationRen, X.,Deng, W.,Yu, F.,Kuang, W.,Na, H.,Yang, S.,Sun, J.,Xu, J.,Shu, B.,Cao, S.,Ke, X.,Deng, Z.,Ning, Y.J.,Zhao, H.
Humanization and engineering of protective antibodies targeting severe fever with thrombocytopenia syndrome virus Gn protein.
Cell Rep, 45:116936-116936, 2026
Cited by
PubMed Abstract: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly lethal tick-borne bunyavirus with no approved therapies. We previously developed a murine-human chimeric antibody S2A5, which provides complete protection against lethal SFTSV infection, but its clinical use is limited by potential immunogenicity and moderate activity against certain genotypes. Here, we systematically humanize and optimize S2A5 using five complementary computational platforms, generating eleven variants and identifying hA5-6, which retains potent neutralizing activity and confers full protection in mice. Structure-guided engineering and in silico mutational analysis further improve antibody function, yielding two optimized hA5-6 variants with up to a 317-fold increase in neutralization potency. Biochemical and functional assays, together with cryo-EM reconstruction of an optimized variant bound to SFTSV virions, indicate that the enhanced activity is associated with improved binding to recombinant Gn and intact virions. This study identifies promising SFTSV therapeutics and establishes a generalizable antibody optimization framework.
PubMed: 41671090
DOI: 10.1016/j.celrep.2026.116936
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.43 Å)
Structure validation

250359

PDB entries from 2026-03-11

PDB statisticsPDBj update infoContact PDBjnumon